DNA topoisomerase 1, Receptor tyrosine-protein kinase erbB-2
Tumor-associated calcium signal transducer 2
Modality
Small molecule
Monoclonal antibody
Phase
FDA-approved
FDA-approved
Therapeutic area
Oncology
Oncology
First approval
—
2020
Mechanism of action
Enhertu
—
Trodelvy
Trodelvy works by binding to the TACI receptor on cancer cells, triggering a cascade of events that ultimately leads to cell death.
Approved indications
Enhertu
Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
Metastatic human epidermal growth factor 2 positive carcinoma of breast
Trodelvy
Triple negative breast neoplasms
Common side effects
Enhertu
Decreased white blood cell count
Decreased hemoglobin
Decreased neutrophil count
Nausea
Increased alanine aminotransferase
Diarrhea
Increased aspartate aminotransferase
Decreased lymphocyte count
Trodelvy
decreased leukocyte count
decreased neutrophil count
decreased hemoglobin
diarrhea
nausea
decreased lymphocyte count
fatigue
alopecia
Boxed warnings
Enhertu
No boxed warnings.
Trodelvy
WARNING: NEUTROPENIA AND DIARRHEA TRODELVY can cause severe, life-threatening, or fatal neutropenia. Withhold TRODELVY for absolute neutrophil count below 1500/mm 3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Primary prophylaxis with G-CSF is recommended for all patients at increased risk of febrile neutropenia [see Dosage and Administration (2.3) ] . Initiate anti-infective treatment in patient with febrile neutropenia without delay [see Warnings and Precautions (5.1) ]. TRODELVY can cause severe diarrhea. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide [see Warnings and Precautions (5.2) ]. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤ Grade 1 and reduce subsequent doses [see Dosage and Administration (2.3) ]. WARNING: NEUTROPENIA AND DIARRHEA See full prescribing information for complete boxed warning . TRODELVY can cause severe, life-threatening, or fatal neutropenia. Withhold TRODELVY for absolute neutrophil count below 1500/mm 3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Primary prophylaxis with G-CSF is recommended for all patients at increased risk of febrile neutropenia. Initiate anti-infective treatment in patients with febrile neutropenia without delay. ( 2.3 , 5.1 ) TRODELVY can cause severe diarrhea. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤ Grade 1 and reduce subsequent doses. ( 2.3 , 5.2 )